Algae Extract for Retinitis Pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests an extract from a type of algae that is rich in a special form of vitamin A. It may help improve vision for people with retinitis pigmentosa caused by certain gene mutations that affect how the eye processes vitamin A.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with retinitis pigmentosa (confirmed by an eye test called an electroretinogram)
- You have a genetic mutation in a gene that affects the retinoid cycle (like RPE65, RDH12, or LRAT) — but not the ABCA4 gene
- You are not currently a smoker
- You are not taking vitamin A or beta-carotene supplements
- You are not pregnant, breastfeeding, or planning to become pregnant without contraception
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an algae-derived powder taken by mouth to see if it can improve visual function in teenagers with retinitis pigmentosa. Because it’s early-stage, it focuses on safety and early signs of benefit to vision tests.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests whether the antibiotic minocycline can slow vision loss from retinitis pigmentosa. If you are between 18 and 60 and have some remaining sight, this study may help find a new treatment.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.